United Therapeutics: Is UTHR Stock Still A Buy At $400?

United Therapeutics (UTHR) stock surged 33% on September 2nd following positive late-stage clinical trial results for its drug Tyvaso in idiopathic pulmonary fibrosis (IPF), a new indication projected to add $4-5 billion in peak sales to the drug's existing $1.6 billion annual revenue. Despite this significant rally, the company is viewed as a compelling buy around $400, underpinned by strong fundamentals, robust revenue growth, high profitability, and a moderate valuation that supports further upside potential.

Analysis

United Therapeutics (UTHR) has demonstrated significant upside potential following positive late-stage clinical trial results for its drug Tyvaso in an idiopathic pulmonary fibrosis (IPF) indication, which triggered a 33% stock surge on September 2nd. The new indication for this already successful therapy, which generated $1.6 billion in sales last year, is projected to add an incremental $4-5 billion in peak sales. The company's financial health is exceptionally strong, characterized by zero debt, a high cash-to-assets ratio of 38.6%, and superior profitability metrics, including a 50.1% operating margin and 40.4% net income margin. Despite the recent rally to approximately $400, valuation remains compelling on a relative basis; its price-to-earnings ratio of 14.7 and price-to-free cash flow ratio of 17.0 are both notably below S&P 500 averages. This fundamental strength is complemented by robust revenue growth, which has averaged 19.9% over the last three years, and demonstrated resilience during prior market downturns. The primary forward-looking risk is emerging competition from Yutrepia, approved in May 2025, which could potentially impact Tyvaso's future pricing power and market share.

Key Decisions for Investors

• Given the potential for Tyvaso to add $4-5 billion in peak sales and the company's superior profitability and zero-debt balance sheet, investors with a 3-5 year horizon should view the stock as a compelling opportunity, even after its recent appreciation.
• Monitor for two key developments: the final FDA approval of Tyvaso for the IPF indication and the market impact of the competitor drug Yutrepia post-May 2025, as this will be critical in assessing future pricing power and market share.
• Despite a price-to-sales ratio of 5.9, which is above the S&P 500, the stock's lower P/E (14.7) and P/FCF (17.0) ratios suggest the valuation has not fully priced in the growth catalyst, supporting the case for continued investment.
• The stock's history of recovering from downturns faster than the S&P 500 suggests it may be a more resilient holding during periods of broad market volatility, a factor to consider for portfolio construction.